Safety and Efficacy of Survodutide in Obesity Management
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Lancet Diabetes Endocrinol 2024 Feb 05;[EPub Ahead of Print], CW le Roux, O Steen, KJ Lucas, E Startseva, A Unseld, AM HennigeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.